AlphaFold predicted structure
MPIG6B · O95866

Mean pLDDT
73.2/ 100
Confident
241 residues
Confidence breakdown
- Very high(≥ 90)39%
- Confident(70–90)20%
- Low(50–70)18%
- Very low(< 50)24%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
megakaryocyte and platelet inhibitory receptor G6b
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Bleeding and platelet disorders
BIALLELIC, autosomal or pseudoautosomalInherited bleeding disorders
BIALLELIC, autosomal or pseudoautosomalCytopenia - NOT Fanconi anaemia
BIALLELIC, autosomal or pseudoautosomalCytopenias and congenital anaemias
BIALLELIC, autosomal or pseudoautosomalthrombocytopenia, anemia, and myelofibrosis
blood platelet disease
Thrombocytopenia
Abnormal bleeding
thrombocythemia 2
hereditary disease
gray platelet syndrome
beta-thalassemia-X-linked thrombocytopenia syndrome
Beta-thalassemia - X-linked thrombocytopenia
acute erythroid leukemia
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Megakaryocyte and platelet inhibitory receptor G6b
Inhibitory receptor that acts as a critical regulator of hematopoietic lineage differentiation, megakaryocyte function and platelet production (PubMed:12665801, PubMed:17311996, PubMed:27743390). Inhibits platelet aggregation and activation by agonists such as ADP and collagen-related peptide (PubMed:12665801). This regulation of megakaryocate function as well as platelet production ann activation is done through the inhibition (via the 2 ITIM motifs) of the receptors CLEC1B and GP6:FcRgamma signaling (PubMed:17311996). Appears to operate in a calcium-independent manner (PubMed:12665801)
MPIG6B · O95866

Mean pLDDT
73.2/ 100
Confident
241 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0